Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis

被引：0

作者：

Coelho, Teresa ^{[1
]}

Whelan, Carol ^{[2
]}

Conceicao, Isabel ^{[3
,4
]}

Brannagan, Thomas ^{[5
]}

Wang, Annabel ^{[6
]}

Polydefkis, Michael ^{[7
]}

Dyck, Peter ^{[8
]}

Plante-Bordeneuve, Violaine ^{[9
]}

Berk, John ^{[10
]}

Merlini, Giampaolo ^{[11
]}

Obici, Laura ^{[11
]}

Drachman, Brian ^{[12
]}

Gorevic, Peter ^{[13
]}

Schmidt, Hartmut ^{[14
]}

Plana, Josep Maria Campistol ^{[15
]}

Gamez, Josep ^{[16
]}

Kristen, Arnt ^{[17
]}

Mazzeo, Anna ^{[18
]}

Narayana, Arvind ^{[19
]}

Olugemo, Kemi ^{[20
]}

Aquino, Peter ^{[21
]}

Benson, Merrill ^{[22
]}

Gertz, Morie ^{[23
]}

机构：

[1] Ctr Hosp Univ Porto, Dept Neurophysiol, Porto, Portugal

[2] Royal Free Hosp, Natl Amyloidosis Ctr, London, England

[3] CHULN, Hosp Santa Maria, Lisbon, Portugal

[4] Univ Lisbon, Dept Neurosci, Fac Med, Lisbon, Portugal

[5] Columbia Univ, Med Ctr, Peripheral Neuropathy Ctr, New York, NY USA

[6] Univ Calif Irvine, Dept Neurol, Orange, CA 92668 USA

[7] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA

[8] Mayo Clin, Peripheral Nerve Res Lab, Rochester, MN USA

[9] CHU Henri Mondor, Dept Neurol, Creteil, France

[10] Boston Univ, Amyloidosis Ctr, Boston, MA 02215 USA

[11] IRCCS Fdn Policlin San Matteo, Amyloidosis Ctr, Pavia, Italy

[12] Penn Presbyterian Med Ctr, Dept Cardiovasc Med, Philadelphia, PA USA

[13] Mt Sinai Med Ctr, Dept Rheumatol, New York, NY 10029 USA

[14] Muenster Univ Hosp, Dept Gastroenterol Hepatol Endocrinol Diabetol &, Munster, Germany

[15] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Barcelona, Spain

[16] Hosp Univ Vall dHebron, Dept Neurol, Barcelona, Spain

[17] Heidelberg Univ Hosp, Amyloidosis Ctr, Heidelberg, Germany

[18] Univ Messina, Dept Neurol, Messina, Italy

[19] Akcea Therapeut, Global Med Affairs, Boston, MA USA

[20] Akcea Therapeut, Clin Dev, Boston, MA USA

[21] Akcea Therapeut, Global Drug Safety & Pharmacovigilance, Boston, MA USA

[22] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[23] Mayo Clin, Bone Marrow Transplant Program, Rochester, MN USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2021年 / 429卷

关键词：

D O I：

10.1016/j.jns.2021.117867

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

117867

引用

页数：3

共 50 条

[31] Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
Adams, David
Tournev, Ivailo L.
Taylor, Mark S.
Coelho, Teresa
Plante-Bordeneuve, Violaine
Berk, John L.
Gonzalez-Duarte, Alejandra
Gillmore, Julian D.
Low, Soon-Chai
Sekijima, Yoshiki
Obici, Laura
Chen, Chongshu
Badri, Prajakta
Arum, Seth M.
Vest, John
Polydefkis, Michael
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 18 - 26
[32] Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
Gales, Luis
PHARMACEUTICALS, 2019, 12 (02)
[33] Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
Velez-Santamaria, Valentina
Nedkova-Hristova, Velina
Morales de la Prida, Moises
Casasnovas, Carlos
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 8677 - 8684
[34] Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy
Mueschen, Lars H.
Koerner, Gudrun
Gingele, Stefan
Haenselmann, Anja
Bavendiek, Udo
Skripuletz, Thomas
MUSCLE & NERVE, 2021, 64 (03) : E11 - E13
[35] MODIFIED NEUROPATHY IMPAIRMENT SCORE+7 COMPONENTS AND LOWER LIMB FUNCTION RESPONSIVENESS IN INOTERSEN TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY
Dyck, P. James
Kincaid, John
Wiessman, Janice
Polydefkis, Michael
Litchy, William
Mauermann, Michelle
Ackermann, Elizabeth
Guthrie, Spencer
Pollock, Michael
Jung, Shiangtung
Baker, Brenda
Dyck, Peter
MUSCLE & NERVE, 2019, 60 : S66 - S66
[36] BUDGET IMPACT OF INOTERSEN FOR THE TREATMENT OF STAGE I OR II POLYNEUROPATHY IN ADULT PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (hATTR) IN PUBLIC HEALTH MEXICO
Soto, H.
Juarez, Escobar Y.
Colmenares, L.
Guzman, Sotoi, I
VALUE IN HEALTH, 2024, 27 (06) : S102 - S102
[37] Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO-TTR
Damy, T. Thibaud
Maurer, M.
Heitner, S.
Drachman, B.
Whelan, C.
Judge, D.
Guthrie, S.
Tai, L.
Hughes, S.
Monia, B.
Ackermann, E.
Benson, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 230 - 230
[38] Treatment Satisfaction for Gene Silencing Pharmacotherapies in Hereditary Transthyretin Amyloidosis with Polyneuropathy
Brown, D.
Kessler, A. Sikora
Llonch, M. Vera
Yarlas, A.
McCausland, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 547 - 547
[39] INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR
Maurer, Mathew S.
Heitner, Stephen
Drachman, Brian
Whelan, Carol
Guthrie, Spencer
Tai, Li
Hughes, Steve G.
Monia, Brett P.
Ackermann, Elizabeth J.
Benson, Merrill D.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 658 - 658
[40] A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Urits, Ivan
Swanson, Daniel
Swett, Michael C.
Patel, Anjana
Berardino, Kevin
Amgalan, Ariunzaya
Berger, Amnon A.
Kassem, Hisham
Kaye, Alan
Viswanath, Omar
NEUROLOGY AND THERAPY, 2020, 9 (02) : 301 - 315

← 1 2 3 4 5 →

Efficacy and safety with &gt;3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis

Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis